Medicus Pharma reports 73% clearance rate in basal cell carcinoma trial

March 9, 2026 7:30 AM

Medicus Pharma Ltd. (NASDAQ: MDCX) reported that its SkinJect microneedle delivery system achieved 73% clinical clearance in patients with basal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found